腹膜透析患者使用西那卡塞：单中心经验

数据集获取（Figshare）

• 源站标题：Cinacalcet in peritoneal dialysis patients: one-center experience
• DOI：10.6084/m9.figshare.19964006.v1
• 发布日期：2022-06-02
• 文件数：2 个
• 文件总体积：445.69 KB
• 源站页面：https://scielo.figshare.com/articles/dataset/Cinacalcet_in_peritoneal_dialysis_patients_one-center_experience/19964006

命令行下载

curl -L -o "7bf591f5b17199106bf5da7d2b5b13ee202c3a0c.jpg" "https://ndownloader.figshare.com/files/35534201"
curl -L -o "9b1aeb896514f72bd3ff11e715b91a81959b047c.jpg" "https://ndownloader.figshare.com/files/35534204"

文件清单

• 7bf591f5b17199106bf5da7d2b5b13ee202c3a0c.jpg（217.84 KB）
• 9b1aeb896514f72bd3ff11e715b91a81959b047c.jpg（227.85 KB）

文件总体积 445.69 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Abstract Introduction: Secondary hyperparathyroidism is the target of several therapeutic strategies, including the use of cinacalcet. Most studies were done only in hemodialysis patients, with few data from peritoneal dialysis patients. Objective: The aim of our work was to evaluate the effectiveness of cinacalcet in secondary hyperparathyroidism in a one-center peritoneal dialysis patients. Methods: A retrospective study was performed in 27 peritoneal dialysis patients with moderate to severe secondary hyperparathyroidism (PTHi > 500 pg/mL with normal or elevated serum calcium levels) treated with cinacalcet. Demographic, clinical and laboratory parameters at the beginning of cinacalcet therapy, second, fourth, sixth months after and at the time it was finished were analyzed. Results: Patients were under peritoneal dialysis at 30.99 ± 16.58 months and were treated with cinacalcet for 15.6 ± 13.4 months; 21 (77.8%) patients showed adverse gastrointestinal effects; PTHi levels at the beginning of cinacalcet therapy were 1145 ± 449 pg/mL. The last PTHi levels under cinacalcet therapy was 1131 ± 642 pg/mL. PTHi reduction was statistically significant at 2 months after the beginning of cinacalcet (p = 0.007) but not in the following evaluations. Conclusion: It is necessary the development of new forms of cinacalcet presentation, in order to avoid gastrointestinal effects adverse factors and to improve therapeutic adherence.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.19964006.v1（source: https://scielo.figshare.com/articles/dataset/Cinacalcet_in_peritoneal_dialysis_patients_one-center_experience/19964006）。